Compare Cytokinetics Inc (CYTK) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs NRG Energy Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while NRG Energy Inc trades at $107.97 (market cap $22.35B). The key difference: NRG Energy Inc is far larger — about 2.6× Cytokinetics Inc's market cap, and NRG Energy Inc pays a 1.79% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and NRG Energy Inc for 63 Days on average.
| CYTK | NRG | |
|---|---|---|
Market Cap | $8.62B | $22.35B |
Volume | 2,594,626 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $87.26 | $184.03 |
52-Week Low | $54.76 | $95.23 |
Typical Hold Time | 19 Days | 63 Days |
Enterprise Value | $8.72B | $46.30B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% today, amid bearish technical signals but strong analyst optimism. The stock shows negative profitability with a -1,321.12% net income margin and P/S ratio of 114, reflecting high growth expectations. Recent Phase 3 trial successes for aficamten in hypertrophic cardiomyopathy position the company for potential FDA approval and commercial expansion, driving the 97% buy rating consensus with a $112.60 price target.
The outlook balances clinical progress against financial strain. While aficamten's recent data and commercial launch of MYQORZO offer significant upside, persistent cash burn and high valuation multiples present substantial risk. Investors face binary outcomes dependent on regulatory success and market penetration versus ongoing operational losses.
NRG Energy trades at $106.32, down 2.11% today, amid mixed earnings results with two recent misses but a Q4 2025 beat. The stock shows a bullish technical signal with support at $104 and resistance at $109. Revenue grew to $30.71 billion in 2025, though net income margin compressed to 2.56%. Recent news highlights a 1.2 GW Texas data center project as a growth driver, while analyst consensus remains strongly bullish with a $202.90 price target.
Outlook is positive due to strong analyst support and strategic investments in data center power, but risks include high debt levels and volatile cash flows. The stock offers potential upside from current levels if execution on new projects meets expectations, though earnings consistency and leverage require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
